Akoya Biosciences, Inc.
AKYA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $81,672 | $96,633 | $74,859 | $54,917 |
| % Growth | -15.5% | 29.1% | 36.3% | – |
| Cost of Goods Sold | $33,794 | $40,328 | $31,469 | $20,699 |
| Gross Profit | $47,878 | $56,305 | $43,390 | $34,218 |
| % Margin | 58.6% | 58.3% | 58% | 62.3% |
| R&D Expenses | $19,745 | $21,889 | $23,211 | $15,701 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $69,317 | $82,381 | $79,653 | $51,016 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $5,546 | $9,703 | $6,734 | $4,726 |
| Operating Expenses | $94,608 | $113,973 | $109,598 | $71,443 |
| Operating Income | -$46,730 | -$57,668 | -$66,208 | -$37,225 |
| % Margin | -57.2% | -59.7% | -88.4% | -67.8% |
| Other Income/Exp. Net | -$8,489 | -$5,615 | -$4,412 | -$3,777 |
| Pre-Tax Income | -$55,219 | -$63,283 | -$70,518 | -$43,075 |
| Tax Expense | $146 | $40 | $123 | -$140 |
| Net Income | -$55,365 | -$63,323 | -$70,641 | -$42,935 |
| % Margin | -67.8% | -65.5% | -94.4% | -78.2% |
| EPS | -1.12 | -1.43 | -1.87 | -1.19 |
| % Growth | 21.7% | 23.5% | -57.1% | – |
| EPS Diluted | -1.12 | -1.43 | -1.87 | -1.19 |
| Weighted Avg Shares Out | 49,419 | 44,435 | 37,747 | 37,424 |
| Weighted Avg Shares Out Dil | 49,419 | 44,435 | 37,747 | 37,424 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,506 | $3,489 | $777 | $91 |
| Interest Expense | $10,429 | $8,761 | $4,554 | $3,115 |
| Depreciation & Amortization | $7,654 | $8,890 | $7,149 | $4,792 |
| EBITDA | -$37,136 | -$45,632 | -$58,815 | -$35,168 |
| % Margin | -45.5% | -47.2% | -78.6% | -64% |